Your browser doesn't support javascript.
loading
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne, Pasi A; van den Heuvel, Michel M; Barlesi, Fabrice; Cobo, Manuel; Mazieres, Julien; Crinò, Lucio; Orlov, Sergey; Blackhall, Fiona; Wolf, Juergen; Garrido, Pilar; Poltoratskiy, Artem; Mariani, Gabriella; Ghiorghiu, Dana; Kilgour, Elaine; Smith, Paul; Kohlmann, Alexander; Carlile, David J; Lawrence, David; Bowen, Karin; Vansteenkiste, Johan.
Afiliación
  • Jänne PA; Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • van den Heuvel MM; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Barlesi F; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France.
  • Cobo M; Department of Medical Oncology, Hospital Universitario Málaga General, Instituto de Investigación Biomédica de Málaga, Malaga, Spain.
  • Mazieres J; Pulmonology Department, Toulouse University Hospital, Toulouse, France.
  • Crinò L; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Meldola, Italy.
  • Orlov S; Department of Medicine, Pavlov Medical University, St Petersburg, Russia.
  • Blackhall F; Manchester University and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
  • Wolf J; Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
  • Garrido P; Medical Oncology Department, University Hospital Ramon y Cajal, Madrid, Spain.
  • Poltoratskiy A; Department for Clinical and Preclinical Trials, Petrov Research Institute of Oncology, St Petersburg, Russia.
  • Mariani G; AstraZeneca, Cambridge, United Kingdom.
  • Ghiorghiu D; AstraZeneca, Cambridge, United Kingdom.
  • Kilgour E; AstraZeneca, Macclesfield, United Kingdom.
  • Smith P; AstraZeneca, Cambridge, United Kingdom.
  • Kohlmann A; AstraZeneca, Cambridge, United Kingdom.
  • Carlile DJ; AstraZeneca, Cambridge, United Kingdom.
  • Lawrence D; AstraZeneca, Cambridge, United Kingdom.
  • Bowen K; AstraZeneca, Gaithersburg, Maryland.
  • Vansteenkiste J; Respiratory Oncology Unit, Department of Respiratory Diseases, University Hospital Katholieke Universiteit Leuven, Leuven, Belgium.
JAMA ; 317(18): 1844-1853, 2017 05 09.
Article en En | MEDLINE | ID: mdl-28492898
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bencimidazoles / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas p21(ras) / Taxoides Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bencimidazoles / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas p21(ras) / Taxoides Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos